Business Wire

Tricentis Named a Leader in the 2019 Gartner Magic Quadrant for Software Test Automation for Fifth Year in a Row

2.12.2019 21:32:00 EET | Business Wire | Press release

Share

Tricentis, leader in Continuous Testing and software test automation, today announced that it has been named a Leader in Gartner’s 2019 Magic Quadrant for Software Test Automation* research report for the fifth consecutive year. Tricentis is the only company that has been recognized as a Leader in each of the last five years. Tricentis was positioned furthest to the right on the completeness of vision axis for the third consecutive year.

Complimentary report access: Gartner 2019 Magic Quadrant for Software Test Automation.

Digital Transformation Requires a Deep-Seated Transformation—Beyond Tools

According to Gartner, “Application leaders driving DevOps initiatives require effective test automation to succeed.”*

“Achieving optimized Continuous Testing isn’t as simple as selecting the ‘best’ test automation tool; it’s a journey that requires commitment to change,” explained Tricentis Founder and Chief Product Officer Wolfgang Platz. “At Tricentis, we’ve had the pleasure of guiding hundreds of top enterprises along this journey—in collaboration with many exceptional quality leaders. In our opinion, being recognized as a Leader in software testing is shared equally with our customers and partners. We feel that we would not have been recognized without their continued support and collaboration.”

Additional Recognitions for Tricentis

Tricentis was also was recognized as a March 2019 Gartner Peer Insights Customers’ Choice for Software Test Automation and scored the highest in the 2018 Gartner Critical Capabilities report for Software Test Automation for the Enterprise End-to-End Testing (3.84/5) and Progressive Web Apps/Responsive Web/Native App (3.83/5) Use Cases.

“Over 1600 global organizations have adopted the Tricentis Continuous Testing Platform to accelerate Digital Transformation,” stated Tricentis CEO Sandeep Johri. “In a market that’s dominated by testing tools, our approach to customer success is focused on testing transformation. The reason for Tricentis’ strong growth is that we partner with our customers to transform their testing process—versus just selling them point tools. These leading enterprises are now consistently delivering differentiating customer/user experiences through software while their less advanced competitors are living on borrowed time.”

*Source: Gartner, “Magic Quadrant for Software Test Automation,” Thomas E. Murphy, Joachim Herschmann, Jim Scheibmeir, November 25, 2019

Disclaimer: Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.

About Tricentis

With the industry's #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases--transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.

Tricentis is the only vendor to achieve "Leader" status in all three top analyst reports (i.e., the "Triple Crown"). This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1600+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent--increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.

Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn, Twitter, and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Wayne Ariola
w.ariola@tricentis.com
(650) 393-3054

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release

NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release

QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems

Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 12:16:00 EEST | Press release

Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its first Latin American market, Peru. It is supported by more than 1,400 laboratory

Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 12:00:00 EEST | Press release

Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO. Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye